Do we need broad immunological work-up in all patients with CIS?

Differences in oligoclonal bands and visual evoked potentials in patients with radiologically and clinically isolated syndrome

“…Nevertheless, a substantial number of CIS patients will have positive ANA without any signs of SLE (9).…”

Should we systematically test patients with clinically isolated syndrome for auto-antibodies?

“…8,9 Some found an association between the presence of auto-Abs and MS clinical course or activity, 9,10 while others did not. 7,[11][12][13][14][15] The prevalence of anti-SSA and SSB in MS varies from 0-13.3% 8,16 and 0-1.7%, 7,8,16,17 respectively. The frequency of concomitant ADs was reported to be from 0-4.8% 9,13,16,17 and 0-16.6% 7,9,13,16,17 in ANA positive (+) and anti-SSA/SSB+ MS patients, respectively.…”

“…7,[11][12][13][14][15] The prevalence of anti-SSA and SSB in MS varies from 0-13.3% 8,16 and 0-1.7%, 7,8,16,17 respectively. The frequency of concomitant ADs was reported to be from 0-4.8% 9,13,16,17 and 0-16.6% 7,9,13,16,17 in ANA positive (+) and anti-SSA/SSB+ MS patients, respectively. In this context, our group has previously reported that the frequency of anti-cardiolipin Abs was similar in typical MS patients compared to healthy controls and that their presence was not related to any clinical characteristic of MS patients or symptoms suggestive of primary Should we systematically test patients with clinically isolated syndrome for auto-antibodies?…”

“…Similarly, both the prevalence of auto-Abs in CIS patients and their role in the differential diagnosis with other ADs have not been fully established. 8,9,17 The main objective of the present study was to evaluate the utility of including the determination of auto-Abs (ANA, anti-SSA and anti-SSB) in the initial work-up of patients with CIS with no initial clinical manifestations suggestive of ADs other than MS. In particular, we aimed: (a) to investigate the prevalence of auto-Abs (ANA, anti-SSA, anti-SSB) within the first year from CIS in an unselected cohort of CIS patients; (b) to assess if auto-Ab positive (auto-Ab+) and negative patients differed at baseline regarding clinical, laboratory and radiological parameters of demyelinating disease; (c) to identify how many auto-Ab+ patients without known ADs at baseline developed ADs during follow-up; and (d) to determine if the clinical, laboratory and radiological characteristics of the patients that developed another AD during follow-up were different from those of the patients that did not develop such kind of disease.…”

“…Similarly, both the prevalence of auto-Abs in CIS patients and their role in the differential diagnosis with other ADs have not been fully established. 8,9,17…”